NYSE:BMYPharmaceuticals
Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb (BMY)?
Earlier this month, Foundation Medicine announced an expanded collaboration with Bristol-Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion for an investigational targeted cancer therapy.
This move underlines Bristol-Myers Squibb’s push deeper into precision oncology, where better patient selection tools could enhance the impact and utilization of its future therapies.
Next, we’ll examine how...